FIM
RXRX icon

FWL Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

FWL Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$169 Hold
55
– – ﹤0.01% 342
2025
Q4 		$225 Sell
55
-745
-93% -$3.69K ﹤0.01% 361
2025
Q3 		$3.9K Buy
800
+30
+4% +$158 ﹤0.01% 296
2025
Q2 		$3.9K Hold
770
– – ﹤0.01% 271
2025
Q1 		$4.07K Buy
770
+145
+23% +$1.06K ﹤0.01% 257
2024
Q4 		$4.22K Buy
+625
New +$4.2K ﹤0.01% 274

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FWL Investment Management's RXRX Position: Q1 2026 in Review

FWL Investment Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 55 shares worth $169. The position accounts for ﹤0.01% of the portfolio, ranked #342.

FWL Investment Management first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.22K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • FWL Investment Management held 55 shares of Recursion Pharmaceuticals worth $169 as of Q1 2026.
  • FWL Investment Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of FWL Investment Management's portfolio in Q1 2026, its #342 holding.
  • FWL Investment Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • FWL Investment Management's Recursion Pharmaceuticals position peaked at $4.22K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on FWL Investment Management's 13F filing for Q1 2026, filed 15 May 2026.